Who We Are
A Strategic Ecosystem for Medical Solutions
3DT Med-Innovations (Drugs, Devices for Diagnostics & Therapeutics)was created to stimulate the inception and growth of start-up companies, with initial focus on cardiovascular disease. Over the years we have expanded our interest and expertise into additional areas such as gastrointestinal and lymphatic dysfunctions.
01.
Incubation Environment
Facility space, shared equipment, and operational infrastructure purpose-built for life sciences start-ups.
02.
Business Guidance
Direct mentoring, strategic business assistance, and access to regulatory expertise from day one.
03.
Capital Network
Curated networking to investors, capital sources, and institutional partners across the industry.
04.
Technical Resources
Contract research services, R&D labs, and specialized technical support at every development stage.
3DT contributes to the discovery of new and useful devices and therapeutics in the treatment of human disease conditions — at scale.
3DT Holdings Mission
20+
years in life sciences
R&D
Contract Research
12+
Portfolio Companies
FDA
Certified Facilities
Certifications & Compliance
ISO 13485
GLP Certified
IACUC Approved
AAALAC
GMP Compliant
FDA 21 CFR Part 820
What We Offer
End-to-End Partner for B2B Life Sciences
Contract Research Services
Full-service preclinical and translational research capabilities. GLP/GMP compliant protocols with dedicated scientific staff.
Facilities & Lab Space
State-of-the-art surgical suites, BSL-2 labs, imaging suites, and shared office infrastructure available to portfolio companies.
Research & Development
Collaborative R&D programs targeting cardiovascular devices, obesity therapeutics, and diagnostic innovations.
Start-up Incubation
Structured incubation with mentorship, regulatory navigation, and access to our network of investors and industry partners.
Portfolio Companies
AccuLab Life Sciences and California Medical Innovations Institute are key operating entities within the 3DT portfolio.
Regulatory Support
FDA 510(k), PMA, and IDE submission support. Expert guidance on clinical study design and regulatory strategy.
Portfolio Highlights
Featured Projects
Active
Conductance Balloon Coronary Post-Dilatation Catheter
Stent malapposition leads to less optimal outcomes (restenosis and thrombosis) in coronary stenting.
Pipeline
Stabilization Device for Trans-septal Access
Transseptal (TS) procedures for accessing the left side of the heart are an important and rapidly growing space for diagnostics and therapy delivery.
Active
Mild Hypothermia Catheter for Reperfusion Injury
ST segment elevation myocardial infarction (STEMI) is the most severe form of acute coronary syndrome (ACS) that affects nearly 500,000 Americans each year and places a heavy clinical and financial burden on the healthcare system.
Sponsors
Partner Organizations
